VALTOCO®
(diazepam nasal spray) CIV

Get to know VALTOCO® (diazepam nasal spray)

VALTOCO is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

VALTOCO optimizes diazepam for nasal delivery using 2 key ingredients: Intravail® technology + vitamin E[1,2]

Specific, individualized dosing[1]

97%

Nearly complete absorption[1,3,4]

91%

91% of seizure episodes used a single dose within 12 hours[5]

Exploratory analysis from an ongoing phase 3, open-label, long-term, repeat-dose study assessing the safety of VALTOCO (the primary study objective) in 177 patients with epilepsy aged 6 to 65 years. In this study, 3,914 seizure episodes were treated with VALTOCO. The study did not have prespecified efficacy endpoints.[5,6]

Treatment-emergent adverse events (TEAEs) were reported regardless of causality. The most common treatment-related TEAEs, defined as those occurring in ≥2 subjects, were nasal discomfort (5.3%), headache (3%), epistaxis (2.3%), cough (1.5%), eye irritation (1.5%), lacrimation increased (1.5%), rhinalgia (1.5%), and somnolence (1.5%).[6]

Sustained plasma levels throughout the day[1,3,4]

Designed for prompt administration by anyone[1]

Generally safe and well tolerated[1]

Flexible savings and support for your patients

To learn more about VALTOCO and sign up to receive information, visit VALTOCOHCP.com.

IMPORTANT SAFETY INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

- **Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.**

Please see reverse for continued Boxed Warning and additional important safety information, and read accompanying full Prescribing Information.

Available in 4 treatment doses[1]

VALTOCO® (diazepam nasal spray) CIV

- 1 blister pack equals 1 complete dose and includes Instructions for Use
- Ready to use; no assembly required
- Each box of VALTOCO (diazepam nasal spray) contains 2 blister packs. Be sure to indicate the number of boxes when prescribing

IMPORTANT SAFETY INFORMATION (CONT.)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS (CONT.)

- **The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.**
- **The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.**

Contraindications: VALTOCO is contraindicated in patients with:
- Hypersensitivity to diazepam
- Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including "gasping syndrome", can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read accompanying full Prescribing Information, including Boxed Warning, for additional important safety information.

References: 1. VALTOCO® (diazepam nasal spray) Prescribing Information. Neurelis, Inc. **2.** Data on file. REF-00253. Neurelis, Inc. **3.** Maglalang PD, Rautiola D, Siegel RA, et al. Rescue therapies for seizure emergencies: new modes of administration. *Epilepsia*. 2018;59(Suppl 2):207-215. **4.** Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. *Epilepsy Res*. 2013;105(3):362-367. **5.** Data on file. REF-00643. Neurelis, Inc. **6.** Wheless JW, Sperling MR, Liow K, et al. Safety of Valtoco® (NRL-1; diazepam nasal spray) in patients with epilepsy: interim results from a phase 3, open-label, 12-month repeat dose study. Poster presented at: American Epilepsy Society 2019 Annual Meeting; December 6-10, 2019; Baltimore, MD.

NEURELIS OUR PASSION IS PROGRESS

NEURELIS, VALTOCO, OUR PASSION IS PROGRESS, and the NEURELIS and VALTOCO logos are trademarks or registered trademarks of Neurelis, Inc. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly-owned subsidiary of Neurelis, Inc.
© Neurelis, Inc. 2021. All rights reserved. US-PRC-21-00051 02/2021